Rapamycin Activates TGF Receptor Independently of Its Ligands: Implications for Endothelial Dysfunction

Rapamycin, the active drug in drug-eluting stents, has a well-recognized antiproliferative action: it binds to FKBP12 and the rapamycin-FKBP complex inhibits the mTOR pathway inducing cell cycle ar...